HLB group stocks closed on the 16th with distinctly mixed movements across individual stocks.

Even among stocks within the same group, a differentiated market trend emerged, with share prices moving in sharply different directions depending on individual supply and demand dynamics and investor sentiment.

Only a handful of stocks posted gains. HLB Life Sciences rose 55 won (2.3%) from the previous trading day to close at 2,380 won, while HLB Pharmaceutical climbed 270 won (3.1%) to finish at 8,850 won, demonstrating strength.

Meanwhile, selling pressure was concentrated on the majority of the remaining stocks. In particular, a string of stocks recorded double-digit declines. HLB Innovation fell 1,600 won (13.3%) to close at 10,360 won, HLB Panagen dropped 223 won (15.5%) to 1,207 won, HLB Pepdo plunged 765 won (15.6%) to 4,135 won, and HLB Biostep declined 305 won (12.6%) to end trading at 2,100 won. HLB Genex also closed down 218 won (11.4%) at 1,682 won.

Among stocks with single-digit losses, HLB (NXT) fell 550 won (1.5%) to 34,150 won, HLB Global dropped 94 won (6.5%) to 1,345 won, and HLB Therapeutics declined 122 won (6.1%) to 1,854 won.

HLB group stocks have exhibited high volatility in recent trading days, repeatedly alternating between sharp rallies and steep declines. Given the magnitude of short-term price swings, market observers note that investors should assess the potential for a short-term rebound alongside recent issues surrounding HLB.

In particular, the key focus going into the new trading week following the Constitution Day holiday closure will be whether the recent volatility persists and whether bargain-hunting buy orders will flow into stocks that have suffered steep losses. Whether the differentiated trend across individual stocks will continue also warrants close scrutiny.

[※ Investors are solely responsible for their investment decisions, and it is essential to review relevant disclosures and company fundamentals before investing.]